Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 21, 1997

View Archived Issues

FTC gives go-ahead for Behring Diagnostics-Dade merger

New antitumor agents discovered at Sagami

Squalene synthase inhibitors in development at Sankyo

Substance P antagonists discovered at Kotobuki

Nonpeptide CRF1 antagonist reduces cerebral infarction in rats

Phase IV trial of Redux

Lovenox superiority established in ESSENCE trial

Roche: 1997 half-year highlights

Laserscope receives approvable letter from FDA

InSite Vision initiates phase II study of ISV-120

Celgene receives patent for SelCID

Theratope vaccine advances to phase III trials

U.S. patent allowed for erectile dysfunction therapy

Millennium reports discovery of new MAD-related proteins

Visualine II receives FDA clearance for marketing

Advisory committee will meet to discuss Synovir NDA

Triangle Pharmaceuticals: Q2 1997 highlights

Non-parenteral insulin formulations for treating IDDM

TNF-alpha inhibitors reported by Centocor

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 23, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for April 21, 2026
Psychedelic space expanding on Trump’s EO
BioWorld
Timothy Leary is dead, but he could be on the outside looking in with a smile on his face as U.S. President Donald Trump’s latest executive order (EO) fuels a...
At AACR: Epigenetic fingerprints in metastases track tumor origin
BioWorld
When a tumor migrates and colonizes another tissue or organ, it can be identified as a metastasis, but its origin is not always clear. Now, a study based on...
In the clinic for April 21, 2026
BioWorld
Clinical updates for biopharma and med tech, including data readouts and publications: Abbott, Agenus, Astrazeneca, Briacell, Clearmind, Greenwich, Intodna,...